Alimera Sciences announced that, as of January 1, 2016, the drug code J7313, which was assigned to Iluvien by the Centers for Medicare and Medicaid, is now active and immediately available. The code, commonly referred to as a "J Code," was added to the Healthcare Common Procedure Coding System and is expected to ease the billing and reimbursement process for physician practices and their patients receiving Iluvien. It has also been confirmed that pricing has been entered into the Part B Average Sales Price consistent with the J Code, according to a company news release.
Alimera's lead product, Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg, is a sustained release intravitreal implant approved in the US to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
"The availability of the Iluvien J Code J7313 on January 1, 2016 will facilitate product reimbursement for physicians, and we believe will improve treatment accessibility for patients suffering from DME," Dan Myers, chief executive officer of Alimera, said in the news release. "We anticipate that the incorporation of the J Code into relevant administrative systems in the first half of 2016 will be welcomed by physicians and their staff, enabling physicians to prescribe ILUVIEN with increased confidence."
Physicians and practice administrators requiring further information about reimbursement for Iluvien should contact Iluvien AccessPlus at 1-844-ILUVIEN (1-844-445-8843) or visit iluvien.com/hcp/accessplus-form.